- Home
- GRNQ vs INAB Comparison
GRNQ vs INAB Comparison
Compare GRNQ & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNQ
- INAB
- Stock Information
- Founded
- GRNQ 2013
- INAB 2016
- Country
- GRNQ Malaysia
- INAB United States
- Employees
- GRNQ N/A
- INAB N/A
- Industry
- GRNQ EDP Services
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- GRNQ Technology
- INAB Health Care
- Exchange
- GRNQ Nasdaq
- INAB Nasdaq
- Market Cap
- GRNQ 10.6M
- INAB 8.7M
- IPO Year
- GRNQ 2018
- INAB 2021
- Fundamental
- Price
- GRNQ $1.43
- INAB $2.10
- Analyst Decision
- GRNQ
- INAB Strong Buy
- Analyst Count
- GRNQ 0
- INAB 2
- Target Price
- GRNQ N/A
- INAB $108.00
- AVG Volume (30 Days)
- GRNQ 21.5K
- INAB 52.4K
- Earning Date
- GRNQ 11-12-2025
- INAB 11-11-2025
- Dividend Yield
- GRNQ N/A
- INAB N/A
- EPS Growth
- GRNQ N/A
- INAB N/A
- EPS
- GRNQ N/A
- INAB N/A
- Revenue
- GRNQ $3,256,679.00
- INAB N/A
- Revenue This Year
- GRNQ N/A
- INAB N/A
- Revenue Next Year
- GRNQ N/A
- INAB N/A
- P/E Ratio
- GRNQ N/A
- INAB N/A
- Revenue Growth
- GRNQ N/A
- INAB N/A
- 52 Week Low
- GRNQ $0.80
- INAB $1.91
- 52 Week High
- GRNQ $2.50
- INAB $16.70
- Technical
- Relative Strength Index (RSI)
- GRNQ 49.03
- INAB 43.89
- Support Level
- GRNQ $1.21
- INAB $1.91
- Resistance Level
- GRNQ $1.50
- INAB $2.26
- Average True Range (ATR)
- GRNQ 0.11
- INAB 0.11
- MACD
- GRNQ 0.01
- INAB -0.01
- Stochastic Oscillator
- GRNQ 57.89
- INAB 48.72
About GRNQ Greenpro Capital Corp.
Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.